Apr 24 |
Those who invested in Imugene (ASX:IMU) five years ago are up 361%
|
Apr 16 |
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
|
Apr 15 |
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
|
Apr 15 |
Imugene opens enrolment for Bile Tract Cancer expansion study
|
Apr 9 |
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
|
Mar 11 |
Imugene progresses onCARlytics solid tumour trial to combination arm
|
Mar 11 |
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
|
Feb 22 |
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
|
Feb 15 |
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial
|
Jan 23 |
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
|